Neuronetics, Inc. announced the new advancements of the NeuroStar® Advanced Therapy system, which enhance both the software and console and continue to build on the Company's innovation momentum. The new software updates provide an enhanced user experience that complements recent MT determination advancements, such as D-Tect™, the MT Cap and Fast MT™. It also unites the TrakStar® platform with NeuroStar, creating a cohesive web-based interface that gives providers a simplified method to build customized, patient-specific treatment protocols for FDA-cleared indications.

The new NeuroStar console will include a 22-inch hi-resolution touchscreen display with a biometric fingerprint reader, allowing for streamlined login. The modern look and functionality of NeuroStar's new widescreen layout upgrades the user interface and allows more information to be displayed during a treatment session. Both software and hardware updates create ample opportunities for future technology expansions.

All NeuroStar consoles utilizing the web-based TrakStar platform will automatically receive the software update with a phased release rolling out in the coming weeks. Upgrade options to the new user interface hardware will be available for current NeuroStar providers. These enhancements follow the recently announced TrakStar upgrades that are now available for all users.